Solara Active Pharma Sciences Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1iq8uj0gyubo14p7i7b3tkca.pdf

Key Takeaways


The Vizag Turnaround

Jitesh Devendra: "The way we have mapped our business plan for Vizag the goal is by Q4 of this fiscal year the Vizag under recovery will not be a burden on our P&L."

Margin Recovery Path

Jitesh Devendra: "We do not see the gross margins declining we only see the gross margins improving and in the second half of this fiscal year it will be better than currently reported results."

Product & Market Mix


CRAMS & Business Development

Jitesh Devendra: "I think where we stand out is in terms of our quality policy as well as the EHS these are the two important factors and of course the reliability and supply which is standard which everyone would ask for."

Regulatory & Site Developments


Balance Sheet & Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
Gross marginReach closer to or achieve 50%Q4 FY23
Vizag P&L burdenVizag under-recovery eliminated; site net breakevenQ4 FY23
Vizag under-recovery run rateRemain at ₹10–11 Crores/quarter until improvement beginsNext quarter
Vizag less regulated market salesCommence sales to markets with no regulatory bindingQ3 FY23
Vizag DMF amendmentsAmend DMFs to include Vizag siteOctober FY23
USFDA inspection (Vizag)Inspection triggered by customersSecond half of next fiscal year
Ibuprofen demandReturn to historical demand levels~6 months
Brazil commercial salesCommercial sales beginFY2025
CRAMS revenue shareContribute 8–10% of total revenuesFY2024
Revenue run rateReturn to historical ₹400 Crores/quarter (annualized)Q4 FY23
Raw material costsNormalization of price increases facedCurrent quarter

Key Metrics

MetricQ1 FY23
Revenue₹337 cr, approximately 80% of historical peak quarterly run rate
Gross margin41.6%
EBITDA₹18.1 cr
EBITDA margin5.4%
Regulated markets revenue share66% of total revenue, up from 58% in FY2022
CRAMS revenue share~5% of total revenue, down from 7% in Q4 FY22
New product sales share5% to 6% of total sales
Debt reduction₹11.7 cr reduced in Q1, no fresh loans availed
Net current assets reduction₹50 cr reduced in Q1, primarily due to inventory reduction
Net debt to EBITDA ratio targetUnder 3.5x, based on annualized Q4 EBITDA
Fixed cost run rate~₹120 cr
Vizag under recovery~₹10 to 11 cr per quarter (per an analyst's math, confirmed by management)
DMF filings planned for FY236 new DMFs, of which 2 from Vizag
Vizag product filings capacityAt least 4 product filings per year
Q4 FY23 revenue target~₹400 cr quarterly run rate on annualized basis
Q4 FY23 gross margin target~50%